Hepatitis C Virus Infection Clinical Trial
Official title:
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection: Real-world Effectiveness and Safety in Taiwan
The investigators aim to assess the effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks in hepatitis C virus (HCV)-infected patients who fail to prior NS5A-containing DAA regimens and HCV genotype 1a and 3 patients who fail to prior non-NS5A-containing DAA regimen in Taiwan on a basis of a multicenter observational study.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | February 28, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - Chronic hepatitis C virus (HCV) infection, defined as the presence of HCV RNA for = 6 months - Age = 20 years - Patients with any HCV genotype (genotype 1-6 or indeterminate genotype) who failed to NS5A-containing DAA regimen or patients with HCV genotype 1a or 3 who failed to non-NS5A-containing DAA regimen Exclusion Criteria: - Decompensated cirrhosis - Patients who receive concomitant medications which are contraindicated for SOF/VEL/VOX, and who decline to stop or switch contraindicated concomitant medications - Patients who receive therapeutic vaccination or other investigational agents for HCV |
Country | Name | City | State |
---|---|---|---|
Taiwan | China Medical University Beigang Hospital | Beigang | |
Taiwan | Changhua Christian Hospital | Changhua | |
Taiwan | Ditmanson Medical Foundation Chiayi Christian Hospital | Chiayi City | |
Taiwan | St. Martin De Porres Hospital | Chiayi City | |
Taiwan | Yang Ming Hospital | Chiayi City | |
Taiwan | Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | Dalin | |
Taiwan | National Taiwan University Hospital, Yun-Lin Branch | Douliu | |
Taiwan | Chi-Mei Medical Center, Liouying | Liuying | |
Taiwan | Fu Jen Catholic University Hospital | New Taipei City | |
Taiwan | China Medical University Hospital | Taichung | |
Taiwan | Chung Shan Medical University Hospital | Taichung | |
Taiwan | Taichung Veterans General Hospital | Taichung | |
Taiwan | National Taiwan University Hospital | Taipei | |
Taiwan | Taipei Medical University Hospital | Taipei | |
Taiwan | Tri-Service General Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sustained virologic response (SVR) | Number and percentage of participants who have undetectable serum level of HCV RNA at off-treatment week 12 | A total of 24 weeks after the initiation of treatment (drug treatment for 12 weeks and off-treatment follow-up for additional 12 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02487030 -
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 | |
Active, not recruiting |
NCT05460130 -
Implementing HCV Treatment for High-risk Populations in Austin, Texas
|
N/A | |
Completed |
NCT02220998 -
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
|
Phase 3 | |
Terminated |
NCT01052090 -
Safety and Efficacy Study in Hepatitis C Patients With PHN121
|
Phase 1/Phase 2 | |
Completed |
NCT02537379 -
Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
|
N/A | |
Recruiting |
NCT04156945 -
Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men
|
N/A | |
Terminated |
NCT02510300 -
A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
|
||
Withdrawn |
NCT04309734 -
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04001608 -
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients
|
Phase 3 | |
Completed |
NCT04112303 -
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
|
Phase 3 | |
Completed |
NCT02251717 -
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection
|
Phase 2 | |
Recruiting |
NCT04005248 -
Prevalence of HCV in HIV-negative MSM
|
N/A | |
Completed |
NCT02249182 -
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
|
Phase 2 | |
Completed |
NCT02939989 -
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
|
Phase 3 | |
Completed |
NCT01718145 -
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
|
Phase 3 | |
Completed |
NCT01482611 -
A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382
|
Phase 1 | |
Completed |
NCT00255177 -
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients
|
Phase 2 | |
Terminated |
NCT02600351 -
Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies
|
Phase 3 | |
Completed |
NCT04980157 -
CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers
|
||
Completed |
NCT02350569 -
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting
|
Phase 2 |